Podcasts about nephropathy

Chegou o episódio escolhido por vocês! Marcela Belleza e Joanne Alves convidam Carol Millon para conversar sobe 6 clinicagens de inibidores de SGLT2, as gliflozinas:Indicações além do DMRisco de CAD euglicêmicaQuando não usar?⁠Cuidados com doença aguda (sick day) e hipovolemia⁠Cuidados pré-operatórioRisco de fratura e amputaçãoReferências:1. Bailey CJ, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. Published 2013 Feb 20. doi:10.1186/1741-7015-11-432. Bersoff-Matcha SJ, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019;170(11):764-769. doi:10.7326/M19-00853. Chang HY, et al. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018;178(9):1190-1198. doi:10.1001/jamainternmed.2018.3034 4. Clar C, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012 Oct 18;2(5):e001007. doi: 10.1136/bmjopen-2012-001007. PMID: 23087012; PMCID: PMC3488745.5. Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5. PMID: 32771263; PMCID: PMC7545583. 6. Fralick M, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. Published 2020 Aug 25. doi:10.1136/bmj.m28127. Li D, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-355. doi:10.1111/dom.128258. Neal B, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.e11. doi:10.1016/j.ahj.2013.05.0079. Nyirjesy P, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173-1178. doi:10.1185/03007995.2012.69705310. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa181174411. Rosenwasser RF, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. PMID: 24348059; PMCID: PMC3848644.12. Sridharan K, Sivaramakrishnan G. Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. Expert Opin Drug Saf. 2025;24(7):797-804. doi:10.1080/14740338.2024.237775513. Ueda P,  et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. Published 2018 Nov 14. doi:10.1136/bmj.k436514. Watts NB, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18. PMID: 26580237; PMCID: PMC4701850.15. Zhuo M, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021;4(10):e2130762. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.3076216. Emerson Cestari Marino, Leandra Anália Freitas Negretto, Rogério Silicani Ribeiro, Denise Momesso, Alina Coutinho Rodrigues Feitosa, Marcos Tadashi Kakitani Toyoshima, Joaquim Custódio da Silva Junior, Sérgio Vencio, Marcio Weissheimer Lauria, João Roberto de Sá, Domingos A. Malerbi, Fernando Valente, Silmara A. O. Leite, Danillo Ewerton Oliveira Amaral, Gabriel Magalhães Nunes Guimarães, Plínio da Cunha Leal, Maristela Bueno Lopes, Luiz Carlos Bastos Salles, Liana Maria Torres de Araújo Azi, Amanda Gomes Fonseca, Lorena Ibiapina M. Carvalho, Francília Faloni Coelho, Bruno Halpern, Cynthia M. Valerio, Fabio R. Trujilho,  Antonio Carlos Aguiar Brandão, Ruy Lyra e Marcello Bertoluci. Rastreamento e Controle da Hiperglicemia no Perioperatório – Posicionamento Conjunto da Sociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Anestesiologia (SBA) e Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (ABESO). Diretriz Oficial da Sociedade Brasileira de Diabetes (2025). DOI: 10.29327/5660187.2025-10 , ISBN: 978-65-5941-367-6.17. Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2024;47(6):933-940. doi:10.2337/dc23-112918. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022;28(9):884-888. doi:10.1016/j.eprac.2022.06.00619. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 Inhibitor-Associated Ketoacidosis vs Type 1 Diabetes-Associated Ketoacidosis. JAMA Netw Open. 2024;7(3):e242744. Published 2024 Mar 4. doi:10.1001/jamanetworkopen.2024.274420. Fleming N, Hamblin PS, Story D, Ekinci EI. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Endocrinol Metab. 2020;105(8):dgaa200. doi:10.1210/clinem/dgaa20021. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-622. Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024-2034. doi:10.1056/NEJMra211501123. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa150472024. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa161192525. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa181238926. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa191130327. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa202219028. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa210703829. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa202481630. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in...

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy

Can you recognize and manage immunoglobulin A nephropathy (IgAN)? Hear from patients and expert faculty on how breakthroughs in therapy could enhance patient outcomes. Credit available for this activity expires: 9/30/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/bridging-gap-case-based-exploration-current-and-emerging-2025a1000q1d?ecd=bdc_podcast_libsyn_mscpedu

Jonathan Barratt, PhD, FRCP - The Gut–Kidney Axis and Beyond in IgA Nephropathy: A New Frontier in Precision Therapy

Jonathan Barratt, PhD, FRCP - The Gut–Kidney Axis and Beyond in IgA Nephropathy: A New Frontier in Precision Therapy

Jonathan Barratt, PhD, FRCP - The Gut–Kidney Axis and Beyond in IgA Nephropathy: A New Frontier in Precision Therapy

Jonathan Barratt, PhD, FRCP - The Gut–Kidney Axis and Beyond in IgA Nephropathy: A New Frontier in Precision Therapy

Drs. Anna Levin and Annika Wernerson discuss the findings from their study, "Transcriptomic Patterns in Adult and Pediatric Patients with IgA Nephropathy or IgA Vasculitis with Nephropathy," with JASN Deputy Editor David H. Ellison.

Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy

Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy

Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy

Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy

Immunoglobulin A nephropathy (IgAN) unveiled: follow the B-cell pathway from mucosal misfire to glomerular damage and discover emerging strategies for smarter care. Credit available for this activity expires: 7/16/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/visual-insights-exploring-disease-modifying-effects-anti-2025a1000ihg?ecd=bdc_podcast_libsyn_mscpedu

Drs Carol H. Wysham and Liana K. Billings discuss how to incorporate SGLT2 inhibitors and GLP-1 receptor agonists into the management of patients with type 2 diabetes and chronic kidney disease. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002049. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview Global, Regional, and National Burden of Chronic Kidney Disease Due to Diabetes Mellitus Type 2 From 1990 to 2021, With Projections to 2036: A Systematic Analysis for the Global Burden of Disease Study 2021 https://pubmed.ncbi.nlm.nih.gov/40034386/ Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR https://pubmed.ncbi.nlm.nih.gov/36514729/ New Creatinine- and Cystatin C-Based Equations to Estimate GFR Without Race https://pubmed.ncbi.nlm.nih.gov/34554658/ Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/38785209/ Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://pubmed.ncbi.nlm.nih.gov/30990260/ Dapagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32970396/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/ Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 https://pubmed.ncbi.nlm.nih.gov/39651975/ CKD Early Identification & Intervention Toolkit https://kdigo.org/wp-content/uploads/2019/01/ISN_KDIGO_EarlyScreeningBooklet_WEB_updatedOct11.pdf Combination Therapy as a New Standard of Care in Diabetic and Non-Diabetic Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/39907542/ Living With Chronic Kidney Disease and Type 2 Diabetes Mellitus: The Patient and Clinician Perspective https://pubmed.ncbi.nlm.nih.gov/36282450/

In this episode, Martina McGrath, MD, FASN, talks with guest editors Laurence H. Beck, Jr., MD, PhD, and Joyita Bharati, MD, about their editorial "A Renaissance of Clinical Trials for IgA Nephropathy" from nephSAP, Vol. 24, No.1 on glomerular diseases.

In this episode, Martina McGrath, MD, FASN, talks with guest editors Laurence H. Beck, Jr., MD, PhD, and Joyita Bharati, MD, about their editorial "A Renaissance of Clinical Trials for IgA Nephropathy" from nephSAP, Vol. 24, No.1 on glomerular diseases.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.Speaker 3: (00:32) Would you mind telling us a little bit about yourself and your background? Speaker 3: (01:58) Would you give us an overview of membranous nephropathy?  Speaker 3: (07:14) Could you tell us a little bit about this new assay? Speaker 3: (14:29) Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past?   

Our experts will take you through patient cases and the latest clinical data for potentially game-changing therapies for patients with IgA nephropathy (IgAN). Credit available for this activity expires: 01/03/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/emerging-iga-nephropathy-advances-digging-deep-b-cell-2024a1000pfe?ecd=bdc_podcast_libsyn_mscpedu

Please visit answersincme.com/NRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of IgA nephropathy (IgAN) discusses novel therapeutic approaches in the management of IgAN. Upon completion of this activity, participants should be better able to: Outline the unmet needs in patients with IgAN; Discuss the clinical implications of new and emerging targeted therapies in IgAN; and Identify patient-centered strategies for long-term management of IgAN.

Dana Rizk, MD - Unlocking the Potential of B-Cell Modulation Therapies in IgA Nephropathy

Today's Episode Charlee reviews chapter 23 from the Pediatric Morning Report book. A 10-year-old female presents to clinic reporting recurrent episodes of burning pain during urina- tion, urinary incontinence, and increased urinary frequency. She has a history of recurrent urinary tract infections (UTIs). The present urinary symptoms started 2 days ago. She denies having fever, chills, nausea, vomiting, abdominal pain, or flank pain. In between these episodes, the child denies having urinary urgency, hesitancy, and incontinence. She has one bowel movement per day and reports no history of constipation. Today's Host Charlee Quarless is a 3rd year medical student at Ross University. About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj www.BeyondThePearls.net The Dr. Raj Podcast Dr. Raj on Twitter Dr. Raj on Instagram Want more board review content? USMLE Step 1 Ad-Free Bundle Crush Step 1 Step 2 Secrets Beyond the Pearls The Dr. Raj Podcast Beyond the Pearls Premium USMLE Step 3 Review MedPrepTGo Step 1 Questions Learn more about your ad choices. Visit megaphone.fm/adchoices

A macrovascular complication of diabetes, diabetic nephropathy is progressive, chronic kidney disease seen in patients with both type 1 and type 2 diabetes mellitus, usually after at least 10 years of hyperglycemia (high blood glucose levels). The three main lesions that are seen in the kidney in patients with diabetes are glomerular lesions, vascular lesions, and pyelonephritis. This brick will focus primarily on the first two of these three lesions; diabetic pyelonephritis is covered in a separate brick. After listening to this AudioBrick, you should be able to: Define diabetic nephropathy. Outline the timeline of progression of diabetic nephropathy (DN) by urine, serum, and histologic criteria. Describe the diagnosis of diabetic nephropathy. Outline the prevention of diabetic nephropathy and, once it is established, how to slow its progression. Describe the management of diabetic nephropathy. You can also check out the original brick from our Renal collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/

Richard Lafayette, MD, FACP - Novel Therapies in Focus: Updates in IgA Nephropathy

Novel therapies for IgA nephropathy are discussed in this ASN Kidney Translation podcast episode, including efficacy and safety of ravulizumab, selective endothelin receptor antagonist SC0062, and long-term results from a study of atacicept as treatment.

Jonathan Barratt, PhD, FRCP - Redefining Hope: The IgA Nephropathy Journey

Jonathan Barratt, PhD, FRCP - Redefining Hope: The IgA Nephropathy Journey

Jonathan Barratt, PhD, FRCP - Redefining Hope: The IgA Nephropathy Journey

Watch this episode to find out how Ira Sahay, meat eater turned vegetarian turned carnivore reversed her autoimmune condition called membranous nephropathy and other accompanying issues. She now coaches patients with autoimmune issues to reverse syndromes their doctors cannot reverse on medications through lifestyle and nutrition interventions. Catch her on X - @theirasahay IG - @ira_sahay

IgA nephropathy, also known as Berger's disease. It's a kidney disease that can affect people without them even realizing it. We'll explain what IgA nephropathy is, what causes it, its symptoms, and how it's treated in simple, easy-to-understand language. _ The Kidney Zone Podcast with Dr. Mo Welcome to the Kidney Zone, where we will dive deep into the fascinating world of our body's remarkable filters. Get ready to unlock the secrets of the kidneys and transplantation as we travel through their pathways, uncovering vital tips, insightful knowledge, and practical advice to keep our kidneys healthy. Whether you're a patient with kidney disease, a medical professional, or simply curious about the kidneys, this is the place for you. _ Follow Along on Social Media: Facebook: https://www.facebook.com/Dr.Mo.Page Instagram: https://www.instagram.com/dr.mo.ibrahim/ Twitter: https://twitter.com/drmoibrahim TikTok: https://www.tiktok.com/@dr.mo.ibrahim _ Dr. Mo Ibrahim is an assistant professor of kidney transplantation at the University of Maryland, Baltimore. He completed his clinical transplant nephrology fellowship at Washington University in 2022. Originally from Cairo, he pursued a physician/scientist career, conducting research at Duke University from 2012 to 2019. He has authored 70+ journal articles, given a TEDx talk, and holds 5 patents. Currently finishing his PhD at Erasmus University, he drives international collaborations to advance medical technology and improve medical monitoring. _ DISCLAIMER The content of this episode is intended for informational purposes only and is not to be considered medical advice. The information presented here is not meant to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare professional or your doctor before making any healthcare decisions or starting any treatment regimen. Individual medical situations can vary, and only a licensed healthcare provider can offer personalized advice tailored to your specific needs. The creators of this episode are not responsible for any actions taken based on the information provided herein. Any reliance on the content of this episode is at your own risk. If you have any medical concerns or questions, please seek guidance from a medical professional promptly. Remember that medical knowledge and practices can evolve over time, and new information may become available after the creation of this episode. Therefore, it is essential to stay up-to-date with the latest medical research and consult with your healthcare provider to ensure the best possible care for your health.

Listen as Dr. London Smith (.com) and his producer Cameron discuss Sickle Cell Nephropathy with special guest David Copperwater (John Dardenne). Not so boring! https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Guest: John Dardenne. Produced by: Dylan Walker Created by: London Smith

Recent advances in our understanding of immunoglobulin A (IgA) nephropathy (IgAN) have led to an abundance of research into new therapies; our experts will guide you through it all. Credit available for this activity expires: 8/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001534?ecd=bdc_podcast_libsyn_mscpedu

Are your patients' kidneys fighting a silent battle? Our experts give insight on earlier detection of IgAN and react to a real patient's experience. Credit available for this activity expires: 8/23/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001513?ecd=bdc_podcast_libsyn_mscpedu

Dive into the fascinating world of immunoglobulin A nephropathy (IgAN), the most common form of primary glomerulonephritis worldwide. Credit available for this activity expires: 7/16/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001351?ecd=bdc_podcast_libsyn_mscpedu

In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases. Episode outline: Seeking and obtaining an IgAN diagnosis Patient self-advocacy Individualizing IgAN treatment plansClinical trial involvement Burdens of IgAN: physical, emotional, social, and beyondTo learn more about IgA nephropathy, find more educational activities and resources with the links below: CME-certified text module with animated pathophysiology video and patient voice audio clipsClinicalThought commentaries Resources on IgAN from the American Kidney Fund 

Listen as Dr. London Smith (.com) and his producer Cameron discuss IgA Nephropathy (Berger Disease) with animal handler Herman Punt (Brennan Lee). Not so boring! https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Guest: Brennan Lee. Produced by: Dylan Walker Created by: London Smith

In this episode of Cardio Buzz, host and guest Dr. Daniel Jones discuss contrast nephropathy, a kidney injury caused by contrast agents used in medical imaging, and a promising intervention to reduce its incidence. Dr. Jones explains that inorganic nitrates, which are naturally found in green leafy vegetables, have shown significant potential in preventing contrast-induced nephropathy and associated acute kidney injuries in a recent study. This study involved 640 high-risk patients and demonstrated that inorganic nitrates reduced kidney injuries by 60% and improved long-term cardiovascular outcomes. The episode concludes with a conversation about the practical implications and future research plans for this intervention.

Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our molecule in development is called atacicept. It targets the immune system in the specific area of B cells, and B cells are the factories of our antibodies, which we need to fight infection over our lifetime. But in patients with autoimmune disease, these B cells are overstimulated, they're overactive, and there are only a few medicines that target B cells with an appropriate balance of safety and efficacy. We had an insight that the science told us that by inhibiting two key factors in the body, BAFF and APRIL, we could normalize that overactivity of B cells and have better outcomes." "Now traditional drug development may be long and expensive. We were very strategic in picking IgA nephropathy. This is an area that has had very little drug development over the last decade. A few small companies started to become interested in this area, and thankfully, because of patient advocacy, the FDA allowed a surrogate endpoint in Phase 3 trials, which made it more efficient to bring this molecule forward. So, there are now two drugs on the market for the first time in the last three or four years, for two new drugs in IgA nephropathy. They don't target B cells, which is really what's driving this disease. They work downstream, or they're nonspecific." "What Vera did differently is that we thought that we could actually demonstrate that kidney function, which in these young patients is declining at an alarming rate, if we could demonstrate that kidney function doesn't decline, that would be meaningful. It would be a significant leap. We don't see that happen in "traditional" drug development often, in my view. So, I think what's different here is that we're picking an area where we think we can intervene and, in early-stage development, show a meaningful improvement in outcomes for patients." #VeraTherapeutics #KidneyDisease #RareDisease #BCells #Immunotherapy #AutoimmuneDiseases #IgANephropathy veratx.com Download the transcript here

Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our molecule in development is called atacicept. It targets the immune system in the specific area of B cells, and B cells are the factories of our antibodies, which we need to fight infection over our lifetime. But in patients with autoimmune disease, these B cells are overstimulated, they're overactive, and there are only a few medicines that target B cells with an appropriate balance of safety and efficacy. We had an insight that the science told us that by inhibiting two key factors in the body, BAFF and APRIL, we could normalize that overactivity of B cells and have better outcomes." "Now traditional drug development may be long and expensive. We were very strategic in picking IgA nephropathy. This is an area that has had very little drug development over the last decade. A few small companies started to become interested in this area, and thankfully, because of patient advocacy, the FDA allowed a surrogate endpoint in Phase 3 trials, which made it more efficient to bring this molecule forward. So, there are now two drugs on the market for the first time in the last three or four years, for two new drugs in IgA nephropathy. They don't target B cells, which is really what's driving this disease. They work downstream, or they're nonspecific." "What Vera did differently is that we thought that we could actually demonstrate that kidney function, which in these young patients is declining at an alarming rate, if we could demonstrate that kidney function doesn't decline, that would be meaningful. It would be a significant leap. We don't see that happen in "traditional" drug development often, in my view. So, I think what's different here is that we're picking an area where we think we can intervene and, in early-stage development, show a meaningful improvement in outcomes for patients." #VeraTherapeutics #KidneyDisease #RareDisease #BCells #Immunotherapy #AutoimmuneDiseases #IgANephropathy veratx.com Listen to the podcast here

The JournalFeed podcast for the week of April 22-26, 2024.These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.Monday Spoon Feed:In a controlled hypoxemia study, pulse oximetry was falsely elevated in subjects with darker skin pigmentation and low perfusion.Friday Spoon Feed:In patients with ACS and concern for STEMI/NSTEMI requiring urgent intervention, randomization to the contrast volume reduction group reduced the rate of acute kidney injury and sustained kidney damage.

Join experts Drs Matthew Sparks and Laurence Beck as they discuss the diagnosis and management of membranous nephropathy, a rare kidney disease. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991606). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview Membranous Glomerulonephritis https://emedicine.medscape.com/article/239799-overview M-type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/19571279/ The Endocytic Receptor Megalin and Its Associated Proteins in Proximal Tubule Epithelial Cells https://pubmed.ncbi.nlm.nih.gov/25019425/ PLA2R Autoantibodies and PLA2R Glomerular Deposits in Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/21323563/ Genome-Wide Association Studies (GWAS) https://www.genome.gov/genetics-glossary/Genome-Wide-Association-Studies Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/25394321/ New 'Antigens' in Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/33380523/ Nephrotic Syndrome https://emedicine.medscape.com/article/244631-overview NAACCR Item #3812: B Symptoms https://staging.seer.cancer.gov/naaccr/item/eod_public/2.1/3812/ Video-Assisted Thoracoscopy https://www.ncbi.nlm.nih.gov/books/NBK532952/ Direct Oral Anticoagulants: A Quick Guide https://pubmed.ncbi.nlm.nih.gov/30416551/ Focal Segmental Glomerulosclerosis https://emedicine.medscape.com/article/245915-overview IgA Nephropathy https://emedicine.medscape.com/article/239927-overview DOAC Compared With Warfarin for VTE in Patients With Obesity: A Retrospective Cohort Study Conducted Through the VENUS Network https://pubmed.ncbi.nlm.nih.gov/36757644/ Is It Lupus Nephritis? A Path to Diagnosis and Treatment https://www.medscape.com/viewarticle/991602 Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy: A Validation Study https://pubmed.ncbi.nlm.nih.gov/34782349/ Noninvasive Diagnosis of Primary Membranous Nephropathy Using Phospholipase A2 Receptor Antibodies https://pubmed.ncbi.nlm.nih.gov/30665573/ Proteinuria Medication https://emedicine.medscape.com/article/238158-medication Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Dapagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32970396/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/ Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/34622104/ Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/35185913/ Transplant Candidate https://kdigo.org/guidelines/transplant-candidate/

A macrovascular complication of diabetes, diabetic nephropathy is progressive, chronic kidney disease seen in patients with both type 1 and type 2 diabetes mellitus, usually after at least 10 years of hyperglycemia (high blood glucose levels). The three main lesions that are seen in the kidney in patients with diabetes are glomerular lesions, vascular lesions, and pyelonephritis. This brick will focus primarily on the first two of these three lesions; diabetic pyelonephritis is covered in a separate brick. After listening to this AudioBrick, you should be able to: Define diabetic nephropathy. Outline the timeline of progression of diabetic nephropathy (DN) by urine, serum, and histologic criteria. Describe the diagnosis of diabetic nephropathy. Outline the prevention of diabetic nephropathy and, once it is established, how to slow its progression. Describe the management of diabetic nephropathy. You can also check out the original brick from our Renal collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/

The kidney is one of the organs necessary to filter blood, composed of tiny functional units that separate waste products from molecules the body should retain. Chronic kidney disease is a significant international problem, with up to 10% of the population requiring treatment, and extreme cases requiring dialysis and/or transplantation with significant personal and public health costs. In today's episode we speak with Dr. Andrew King, Chief Scientific Officer of Chinook Therapeutics.  We discuss rare diseases of the kidney, such as disorders that lead to nephropathy, proteinuria, and oxalic acid deposition, along with how the next generation of drugs work to target these issues. www.chinooktx.com